20:07 , Dec 1, 2016 |  BC Week In Review  |  Company News

BromSite sales and marketing update

Sun launched BromSite bromfenac in the U.S. to treat postoperative inflammation and prevent pain during cataract surgery. BromSite consists of low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained delivery technology from Sun's...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Sep 21, 2015 |  BC Week In Review  |  Company News

InSite, Sun Pharmaceutical deal

Sun’s Ranbaxy Inc. subsidiary will acquire InSite for $0.35 per share or about $48 million. The price is a 3% premium to InSite’s close of $0.34 on Sept. 14, the day before the deal was...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

BromSite regulatory update

InSite submitted an NDA to FDA for BromSite to treat inflammation and prevent pain in cataract surgery. BromSite is low-dose bromfenac, an NSAID, delivered via InSite’s DuraSite sustained delivery technology. Last week, QLT Inc. (TSX:QLT;...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

InSite, QLT deal

QLT will acquire InSite in a stock deal. Last week, InSite submitted an NDA to FDA for BromSite to reduce postoperative inflammation and prevent pain after cataract surgery. BromSite is low-dose bromfenac, an NSAID, delivered...
07:00 , Jun 15, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

InSite, Nicox deal

InSite granted Nicox exclusive rights to develop, manufacture and commercialize AzaSite , BromSite and AzaSite Xtra in Europe, the Middle East and Africa. Nicox expects to submit MAAs for AzaSite and BromSite in 1Q16 and...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Summer lull

With Vertex Pharmaceuticals Inc. already having delivered 2014's most anticipated data and Gilead Sciences Inc. having rolled out the year's most keenly watched launch, buysiders expect a quiet 3Q14 and plan to use the lull...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

BromSite: Phase III data

Top-line data from 234 patients who underwent cataract surgery in the modified intent-to-treat (mITT) population of a double-blind Phase III trial showed that twice-daily BromSite met the primary endpoint of reducing post-surgical ocular inflammation from...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

BromSite: Completed Phase III enrollment

InSite completed enrollment of about 240 patients undergoing cataract surgery in a double-blind Phase III trial comparing twice-daily BromSite vs. the DuraSite vehicle alone. Patients will receive BromSite the day prior to surgery, the day...